Trends in the Use of Bone Morphogenetic Protein as a Substitute to Autologous Iliac Crest Bone Grafting for Spinal Fusion Procedures in the United States
Authors:
- Shivanand P. LadSLShivanand P. Lad
- Jay K. NathanJNJay K. Nathan
- Maxwell BoakyeMBMaxwell Boakye
- 1 February 2011
- journal article
- Published by Wolters Kluwer Health in Spine
- Vol. 36 (4) , E274-E281
Abstract
Analysis of Nationwide Inpatient Sample (NIS) database for data related to spinal fusion procedures. To identify trends in the use of bone morphogenetic protein (BMP) versus iliac crest bone grafts in various spinal fusion procedures performed in the United States, explore stratification by patient demographics, and analyze the impact on treatment cost. BMP has been shown to achieve better clinical outcomes in anterior lumbar interbody fusions procedures, which led to its Food and Drug Administration approval for this indication in 2002. Since then, significant off-label use has occurred, without a full description of the results. We searched the NIS for data relating to BMP administration or iliac crest bone grafting in a variety of spinal fusion procedures performed from 1993 to 2006, based on International Classification of Diseases, Ninth Revision classification. The NIS is the largest all-payer inpatient care database, with demographic, outcome, and cost data from approximately eight million annual patient discharges throughout the United States. Demographics among patients treated with BMP versus iliac crest bone graft were compared to reduce the likelihood of bias in the analysis. BMP became applied more frequently in each type of spinal fusion procedure examined over our study period, with the exception of anterior lumbar interbody fusions. Patients receiving iliac crest bone grafts versus BMP exhibited very similar demographic characteristics, including age, socioeconomic status, and type of health care setting. Although BMP typically increased the cost of the procedure itself, it improved outcomes and shorter hospital stays often provided a net benefit. BMP is increasingly being used in spinal fusion procedures, including ones for which it is not officially approved, because of the surgical and postsurgical benefits it provides. Given the morbidity that this may entail, monitoring outcomes trends will help to inform guidelines for BMP use and ensure that its benefits continue to outweigh its costs.Keywords
This publication has 11 references indexed in Scilit:
- Efficacy of Autologous Iliac Crest Bone Graft and Bone Morphogenetic Proteins for Posterolateral Fusion of Lumbar SpineSpine, 2008
- Bone Morphogenetic Protein (RhBMP-2) as a Substitute for Iliac Crest Bone Graft in Multilevel Adult Spinal Deformity SurgerySpine, 2008
- The perioperative cost of Infuse bone graft in posterolateral lumbar spine fusionThe Spine Journal, 2008
- Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion: a case studyThe Spine Journal, 2007
- Use of Recombinant Human Bone Morphogenetic Protein-2 as an Adjunct in Posterolateral Lumbar Spine FusionJournal of Spinal Disorders & Techniques, 2006
- Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein—2Journal of Neurosurgery: Spine, 2005
- Anterior cervical discectomy and fusion involving a polyetheretherketone spacer and bone morphogenetic proteinJournal of Neurosurgery: Spine, 2005
- Bone morphogenetic proteins in anterior lumbar interbody fusion: old techniques and new technologiesJournal of Neurosurgery: Spine, 2004
- Use of Recombinant Human Bone Morphogenetic Protein-2 to Achieve Posterolateral Lumbar Spine Fusion in HumansSpine, 2002
- Overview of the Biology of Lumbar Spine Fusion and Principles for Selecting a Bone Graft SubstituteSpine, 2002